Revista de Gastroenterología de México, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Russian Journal of Allergy, Год журнала: 2025, Номер unknown
Опубликована: Март 6, 2025
Aim: to systemize existing data on the treatment strategies for patients with eosinophilic esophagitis. Eosinophilic esophagitis is a T2- disease characterized by infiltration of esophageal mucosa, subepithelial and submucosal fibrosis, progressive dysphagia. Early diagnosis appropriate can prevent development strictures other complications. The includes use elimination diets, pharmacological therapy, endoscopic dilation or bougienage strictures. most effective drugs achieving clinical histological remission in are proton pump inhibitors, topical glucocorticosteroids, biological agents represented monoclonal antibodies. Over time, advantages systemic antibody therapies (anti-IL4/IL-13) over inhibitors glucocorticosteroids have become evident, particularly terms their impact mucosal inflammation remodeling wall. Currently, only approved anti-interleukin drug dupilumab, which has demonstrated high efficacy safety trials children aged 1 year older, as well adults. Endoscopic performed who stenosis (with an diameter 13 mm) following course pharmacotherapy. To this day, numerous questions remain regarding maintenance its duration, predictors progression. With emergence new biologic esophagitis, accessibility, long-term efficacy, critically important considerations.
Язык: Английский
Процитировано
0
Revista de Gastroenterología de México (English Edition), Год журнала: 2025, Номер unknown
Опубликована: Апрель 1, 2025
Язык: Английский
Процитировано
0
Healthcare, Год журнала: 2025, Номер 13(8), С. 923 - 923
Опубликована: Апрель 17, 2025
Pediatric gastroenterology is entering a pivotal phase marked by significant challenges and emerging opportunities in treating conditions like celiac disease (CeD), eosinophilic esophagitis (EoE), inflammatory bowel (IBD), autoimmune hepatitis (AIH) pose clinical hurdles, but new therapeutic avenues are emerging. Advances precision medicine, particularly proteomics, reshaping care tailoring treatments to individual patient characteristics. For CeD, therapies gluten-degrading enzymes (latiglutenase, Kuma030) zonulin inhibitors (larazotide acetate) show promise, though outcomes inconsistent. Immunotherapy microbiota modulation, including probiotics fecal transplantation (FMT), also under exploration, with potential benefits symptom management. Transglutaminase 2 ZED-1227 could help prevent gluten-induced damage. Monoclonal antibodies targeting immune pathways, such as AMG 714 larazotide acetate, require further validation pediatric populations. In EoE, biologics dupilumab, cendakimab, dectrekumab (IL-13 inhibitors), mepolizumab, reslizumab, benralizumab (IL-5/IL-5R inhibitors) varying efficacy, while thymic stromal lymphopoietin (TSLP) tezepelumab being investigated. These more pediatric-specific research optimize their use. IBD, vedolizumab, ustekinumab, risankizumab, well small molecules tofacitinib, etrasimod, upadacitinib, treatments. New medications for individuals refractory or steroid-dependent AIH have been explored. Personalized therapy, integrating drug monitoring, lifestyle changes, increasingly guiding IBD This narrative review explores recent breakthroughs AIH, focus on studies when available, discusses the growing role of proteomics advancing personalized gastroenterological care.
Язык: Английский
Процитировано
0
World Allergy Organization Journal, Год журнала: 2024, Номер 17(10), С. 100968 - 100968
Опубликована: Сен. 23, 2024
Язык: Английский
Процитировано
1
Brazilian Journal of Implantology and Health Sciences, Год журнала: 2024, Номер 6(8), С. 535 - 545
Опубликована: Авг. 4, 2024
Introdução: A esofagite eosinofílica tem crescido nos últimos anos. Seus sintomas são incapacitantes e trazem prejuízos na qualidade de vida seus portadores. O tratamento convencional falha em muitos casos. imunobiológico dupilumabe se apresenta como alternativa no dessa doença, por meio do bloqueio da atividade Interleucina IL-4 IL-13. Metodologia: Realizou-se uma pesquisa bibliográfica nas plataformas Scielo, Biblioteca Virtual Saúde PubMed. No total, foram identificadas 1268 publicações, com os descritores “esofagite eosinofílica” “dupilumabe”. Após avaliação metodológica, 22 publicações entre 2019 2024 português, espanhol inglês incluídas. Resultados Discussão: foi capaz reduzir as contagens eosinófilos esofágicos melhorar significativamente a histologia esôfago todas apresentações doença. tipo fibroestenótico, medicação conseguiu remissão 100% dos casos estudados. Ademais, apresentou resultados excelentes quando utilizado portadores outras patologias atópicas concomitantes. Em alguns estudos, visualizada capacidade melhoria funcionalidade esôfago. alívio registrado maioria mas não houve unanimidade. Conclusão: representa um importante aliado refratária à medicações primeira linha. Entranto, seu alto custo recente incorporação ao acervo terapêutico doença constituem desafios serem superados. É necessário realização novos principalmente longo prazo, sobre eficácia droga, dose duração necessárias.
Процитировано
0
Salud Ciencia y Tecnología, Год журнала: 2024, Номер 5, С. 1080 - 1080
Опубликована: Окт. 25, 2024
Introduction: Eosinophilic esophagitis is a chronic disease characterized by the accumulation of eosinophils in esophageal wall, causing inflammation and damage to mucosa, which can affect swallowing ability. Despite being an idiopathic disease, it believed that several factors may trigger overproduction eosinophils. Diagnosis made through endoscopy, where mucosa examined, biopsy taken detect presence tissue. Treatment multidisciplinary, including dietary modifications (such as restricting foods inflammatory response) pharmacological therapy. In severe cases, dilations also be considered relieve narrowing.Methods: Data were collected from articles indexed Scopus, PubMed, Scielo, Elsevier, considering bibliographies English Spanish 2017 2024. For this investigation, 72 used references.Results: After analyzing selected articles, important aspects eosinophilic identified. Various studies concluded prevalence pathology has increased recent years, with higher incidence cases Western countries, suggesting possible link environmental factors. This affects both children adults, frequency men.Conclusions: The analysis bibliographic sources research reveals that, despite discovered just over 30 years ago, remains affecting diverse population regardless age. Studies show exact reasons why certain individuals are more susceptible than others have not been determined, complex interaction between genetic, immunological,
Язык: Английский
Процитировано
0
Revista de Gastroenterología de México, Год журнала: 2024, Номер unknown
Опубликована: Ноя. 1, 2024
Процитировано
0